The US approach to biosimilars: the long-awaited FDA approval pathway.
about
Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.Biosimilars: part 2: potential concerns and challenges for p&t committees.Biosimilars: part 1: proposed regulatory criteria for FDA approval.Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.
P2860
The US approach to biosimilars: the long-awaited FDA approval pathway.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The US approach to biosimilars: the long-awaited FDA approval pathway.
@en
type
label
The US approach to biosimilars: the long-awaited FDA approval pathway.
@en
prefLabel
The US approach to biosimilars: the long-awaited FDA approval pathway.
@en
P1433
P1476
The US approach to biosimilars: the long-awaited FDA approval pathway.
@en
P2093
Begoña Calvo
Leyre Zuñiga
P2860
P304
P356
10.2165/11635830-000000000-00000
P577
2012-12-01T00:00:00Z